IBRX: Rounding Bottom detected on 24 Mar 2026

IBRX is forming a rounding-bottom pattern with a secondary post-collapse-recovery structure detected over 9 days. The stock trades at $9.40, positioned 413.66% above its 52-week low of $1.95 but 24.38% below its 52-week high of $12.43. Pattern quality scores remain moderate: structure at 12.5/15, volume at 12.0/12, and breakout at 13.0/13, generating an overall score of 70.5/98 with 63.67% historical win probability. Key resistance sits at $2.72, while the critical support floor is $1.95. The setup suggests modest structural confirmation with sufficient volume breadth to support a breakout attempt.

ImmunityBio reported full-year 2025 net product revenue of approximately $113 million for ANKTIVA, representing a 700% increase year-over-year, with a 750% increase in unit sales volume and 20% quarter-over-quarter growth in Q4 2025. On March 9, 2026, the company resubmitted a supplemental BLA to the FDA for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary-only tumors, with the partnership deploying an 85-person salesforce across 30 countries and ANKTIVA authorized across 33 countries including EU conditional marketing authorization in February 2026. On March 17, the NCCN updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG. BTIG initiated coverage with a Buy rating and $13 price target. The March 2, 2026 earnings report posted EPS of -$0.06, beating analyst expectations of -$0.09. This rapid commercialization and regulatory momentum occurred just before the pattern formed, providing fundamental tailwinds for technical recovery.

A successful rounding-bottom breakout would target $10.03 (conservative measured move), with the pattern requiring sustained volume confirmation above current resistance to trigger momentum. Historical data from the 63.67% win-probability score suggests favorable technical follow-through once resistance is decisively breached. The setup invalidates below the key support level of $1.95—a drop exceeding 79% from current price—which would suggest pattern failure. Given the moderate pattern quality scores (structure 12.5, breakout 13.0, volume 12.0) and moderate overall score of 70.5, the pattern indicates a tradeable recovery bounce rather than a high-conviction major reversal, with the target suggesting an 6.7% upside from current levels within the breakout window.

The company reported a trailing twelve-month net loss of $351.4 million with diluted EPS of -$0.38 against $113.29 million in revenue, highlighting substantial burn rate and profitability challenges. The next earnings call is scheduled for May 11, 2026, creating event risk over the next 7 weeks. The valuation thesis hinges on ANKTIVA expanding beyond bladder cancer and regulators supporting broader indications, both of which could play out very differently. The stock exhibits elevated volatility at 1.199 (20-day), with beta at 1.08, amplifying downside moves in a bearish sector regime (score -0.33). Recent gains of 349.76% over 3 months create elevated profit-taking risk, particularly after a 14.49% weekly surge. RSI at 59.69 approaches neither overbought nor oversold zones, but the pattern's weak structural quality (12.5/15) and low volume ratio (0.84x average) suggest limited institutional conviction despite recent catalysts. Regulatory uncertainty on the papillary-only indication and reimbursement execution remain key execution risks.